Kelun-Biotech says Phase 3 sac-TMT plus Keytruda meets PFS endpoint in first-line PD-L1-negative NSCLC

• Sichuan Kelun-Biotech reported its Phase 3 OptiTROP-Lung06 study met the primary endpoint of progression-free survival at interim analysis.
• Trial tested TROP2 ADC sacituzumab tirumotecan (sac-TMT) with Merck’s Keytruda versus chemotherapy with Keytruda in first-line PD-L1-negative non-squamous NSCLC.
• Combination showed a statistically significant, clinically meaningful PFS improvement; overall survival trended positive.
• Safety profile matched prior studies; no new safety signals flagged.
• Company plans talks with China’s NMPA drug review center on a potential regulatory pathway based on the results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12244468), on July 14, 2026, and is solely responsible for the information contained therein.